AC-203

Phase 2Small molecule

TTWi Biotechnology, Inc.

AC-203 is one of 33 small molecule programs targeting Bullous Pemphigoid. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bullous PemphigoidActive, not recruiting

Epidermolysis Bullosa SimplexActive, not recruiting

Generalized Epidermolysis Bullosa SimplexActive, not recruiting

Bullous PemphigoidPhase 2

Active, not recruiting

Epidermolysis Bullosa SimplexPhase 2/Phase 3

Active, not recruiting

Generalized Epidermolysis Bullosa SimplexPreclinical

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Bullous Pemphigoid

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Approved

1 2

Rayos

RRoxane Laboratories

Approved

3 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Avlosulfon

AAlmirall, S.A.

Approved

1 5

Imuran

LLegacy Health System

Rituxan

2 7

Xolair

Roche

Phase 3

1 8

Fasenra

AstraZeneca

Phase 3

1 9

Vyvgart

Argenx

Phase 3

2 10

Mabthera

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Generalized Epidermolysis Bullosa Simplex

NCT06073132

Clinical

Trials by Indication[1]

Bullous Pemphigoid1 trial

A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid

Terminated·TTWi Biotechnology, Inc.·Phase 2·NCT03286582·10 enrolled

Double-blind1 trial

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

Completed·TTWi Biotechnology, Inc.·Phase 2·NCT03468322·9 enrolled

Generalized Epidermolysis Bullosa Simplex1 trial

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]

Active, not recruiting·TTWi Biotechnology, Inc.·Preclinical·NCT06073132·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AC-203. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AC-203 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AC-203. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TWi Biotechnology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTWi Biotechnology, Inc.

AC-203

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Bullous Pemphigoid1 trial

Double-blind1 trial

Generalized Epidermolysis Bullosa Simplex1 trial

References

Drug Info

Quick Facts

Related News